Correlation of Primary Tumor FDG Uptake with Clinicopathologic Prognostic Factors in Invasive Ductal Carcinoma of the Breast

详细信息    查看全文

• 作者：I. Jo (1)
  Seok Kil Zeon (4)
  Sung Hoon Kim (1)
  Hae Won Kim (1)
  Sun Hee Kang (2)
  Sun Young Kwon (3)
  Su Jin Kim (5)
  
  1. Department of Nuclear Medicine ; Keimyung University ; School of Medicine ; Daegu ; Republic of Korea
  4. Department of Nuclear Medicine ; Bundang Jesaeng General Hospital ; Seohyeon-dong 255-2 ; Seongnam ; Republic of Korea
  2. Department of Surgery ; Keimyung University ; School of Medicine ; Daegu ; Republic of Korea
  3. Department of Pathology ; Keimyung University ; School of Medicine ; Daegu ; Republic of Korea
  5. Department of Anesthesiology and Pain Medicine ; Dongguk University ; School of Medicine ; Gyeongju ; Republic of Korea
  
• 关键词：F ; 18 FDG ; PET/CT ; Breast cancer ; Triple negative ; Invasive ductal carcinoma
• 刊名：Nuclear Medicine and Molecular Imaging
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：49
• 期：1
• 页码：19-25
• 全文大小：347 KB
• 参考文献：1. Jung, KW, Park, S, Won, YJ, Kong, HJ, Lee, JY, Park, EC (2011) Prediction of cancer incidence and mortality in Korea, 2011. Cancer Res Treat 43: pp. 12-8 4143/crt.2011.43.1.12" target="_blank" title="It opens in new window">CrossRef
  2. Kim, JE, Ahn, HJ, Ahn, JH, Yoon, DH, Kim, SB, Jung, KH (2012) Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer. J Breast Cancer 15: pp. 197-202 4048/jbc.2012.15.2.197" target="_blank" title="It opens in new window">CrossRef
  3. Yeo, JS, Lee, DS, Kang, KW, Noh, DY, Chung, JK, Lee, MC (1999) Differential diagnosis of breast mass and staging of breast cancer using F-18-FDG PET. Nucl Med Mol Imaging 33: pp. 502-11
  4. Tantiwongkosi, B, Yu, F, Kanard, A, Miller, FR (2014) Role of (18) F-FDG PET/CT in pre and post treatment evaluation in head and neck carcinoma. World J Radiol 6: pp. 177-91 4329/wjr.v6.i5.177" target="_blank" title="It opens in new window">CrossRef
  5. Marcus, C, Whitworth, PW, Surasi, DS, Pai, SI, Subramaniam, RM (2014) PET/CT in the management of thyroid cancers. AJR Am J Roentgenol 202: pp. 1316-29 4/AJR.13.11673" target="_blank" title="It opens in new window">CrossRef
  6. Ian, JR, Fiona, H, Malcolm, RK (2011) FDG-PETCT in the staging of localregional metastases in breast cancer. Breast 20: pp. 491-4 CrossRef
  7. Yoon, JK (2008) Clinical application of 18鈥塅-FDG PET in breast cancer. Nucl Med Mol Imaging 42: pp. 76-90
  8. Song, BI, Hong, CM, Lee, HJ, Kang, SM, Jeong, SY, Kim, HW (2011) Prognostic value of primary tumor uptake on F-18 FDG PET/CT in patients with invasive ductal breast cancer. Nucl Med Mol Imaging 45: pp. 117-24 CrossRef
  9. Kim, JH, Yoo, SW, Kang, SR, Cho, SG, Oh, JR, Chong, AR (2012) Prognostic significance of metabolic tumor volume measured by 18鈥塅-FDG PET/CT in operable primary breast cancer. Nucl Med Mol Imaging 46: pp. 278-85 CrossRef
  Edge, SB, Byrd, DR, Compton, CC, Fritz, AG, Greene, FL, Trotti, A eds. (2010) AJCC cancer staging manual. NY, Springer, New York
  10. Elston, CW, Ellis, IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathol 19: pp. 403-10 CrossRef
  11. Wolff, AC, Hammond, ME, Schwartz, JN, Hagerty, KL, Allred, DC, Cote, RJ (2007) American society of clinical oncology/college of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: pp. 118-45 CrossRef
  12. Pennant, M, Takwoingi, Y, Pennant, L, Davenport, C, Fry-Smith, A, Eisinga, A (2010) A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technol Assess 14: pp. 1-103 4500" target="_blank" title="It opens in new window">CrossRef
  13. Simpson, JF, Gray, R, Dressler, LG, Cobau, CD, Falkson, CI, Gilchrist, KW (2000) Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern cooperative oncology group companion study, EST 4189. J Clin Oncol 18: pp. 2059-69
  14. Nguyen, PL, Taghian, AG, Katz, MS, Niemierko, A, Abi Raad, RF, Boon, WL (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26: pp. 2373-8 4.4287" target="_blank" title="It opens in new window">CrossRef
  15. Wang, CL, MacDonald, LR, Rogers, JV, Aravkin, A, Haseley, DR, Beatty, JD (2011) Positron emission mammography: correlation of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status and 18鈥塅-FDG. AJR Am J Roentgenol 197: pp. 247-55 4/AJR.11.6478" target="_blank" title="It opens in new window">CrossRef
  16. Basu, S, Chen, W, Tchou, J, Mavi, A, Cermik, T, Czerniecki, B (2008) Comparison of triple-negative and ER+, PR+, HER2- breast carcinoma using quantitative F-18 FDG PET imaging parameters. Cancer 112: pp. 995-1000 CrossRef
  17. Groheux, D, Giacchetti, S, Moretti, JL, Porcher, R, Espi茅, M, Lehmann-Che, J (2011) Correlation of high 18鈥塅-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 38: pp. 426-35 40-9" target="_blank" title="It opens in new window">CrossRef
  18. Kim, BS, Sung, SH (2012) Usefulness of 18鈥塅-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer. Ann Nucl Med 26: pp. 175-83 49-011-0556-1" target="_blank" title="It opens in new window">CrossRef
  19. Vinh-Hung, V, Everaert, H, Lamote, J, Voordeckers, M, Parijs, H, Vanhoeij, M (2012) Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer. Eur J Nucl Med Mol Imaging 39: pp. 1618-27 CrossRef
  20. Koolen, BB, Vrancken Peeters, MJ, Wesseling, J, Lips, EH, Vogel, WV, Aukema, TS (2012) Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 39: pp. 1830-8 CrossRef
  21. Berriolo-Riedinger, A, Touzery, C, Riedinger, JM, Toubeau, M, Coudert, B, Arnould, L (2007) [18鈥塅] FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 34: pp. 1915-24 459-5" target="_blank" title="It opens in new window">CrossRef
  22. Kong, EJ, Chun, KA, Cho, IH, Lee, SJ (2010) 18鈥塅-FDG PET/CT with contrast enhancement for evaluation of axillary lymph node involvement in T1 breast cancer. Nucl Med Mol Imaging 44: pp. 170-6 CrossRef
  23. David, G, Sylvie, G, Jean-Luc, M, Raphael, P, Marc, E, Jacqueline, L (2011) Correlation of high 18鈥塅-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 38: pp. 426-35 40-9" target="_blank" title="It opens in new window">CrossRef
  24. Heudel, P, Cimarelli, S, Montella, A, Bouteille, C, Mognetti, T (2010) Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol 15: pp. 588-93 47-010-0120-3" target="_blank" title="It opens in new window">CrossRef
  25. Ueda, S, Tsuda, H, Asakawa, H, Shigekawa, T, Fukatsu, K, Kondo, N (2008) Clinicopathological and prognostic relevance of uptake level using 18鈥塅-fluorodeoxyglucose positron emission tomography /computed tomography fusion imaging (18鈥塅-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol 38: pp. 250-8 CrossRef
  26. Haffty, BG, Yang, Q, Reiss, M, Kearney, T, Higgins, SA, Weidhaas, J (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24: pp. 5652-7 4" target="_blank" title="It opens in new window">CrossRef
  27. Rebecca, D, Maureen, T, Kathleen, P, Wedad, H, Harriet, K, Carol, S (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: pp. 4429-34 432.CCR-06-3045" target="_blank" title="It opens in new window">CrossRef
  28. Bauer, KR, Brown, M, Cress, RD, Parise, CA, Caggiano, V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109: pp. 1721-8 CrossRef
  
• 刊物主题：Nuclear Medicine; Imaging / Radiology; Orthopedics; Cardiology; Oncology;
• 出版者：Springer Berlin Heidelberg
• ISSN：1869-3482

文摘

Purpose The purpose of this study was to investigate the correlation of primary tumor FDG uptake to clinicopathological prognostic factors in invasive ductal carcinoma of the breast. Methods We retrospectively reviewed 136 of 215 female patients with pathologically proven invasive ductal breast cancer from January 2008 to December 2011 who underwent F-18 FDG PET/CT for initial staging and follow-up after curative treatment with analysis of estrogen receptor (ER), progesterone receptor (PR) and human epithelial growth factor receptor 2 (HER2). The maximum standardized uptake value (SUVmax) of the primary breast tumor was measured and compared with hormonal receptor and HER2 overexpression status. Results The high SUVmax of primary breast tumors is significantly correlated with the clinicopathological factors: tumor size, histologic grade, TNM stage, negativity of ER, negativity of PR, HER2 overexpression and triple negativity. The recurrent group with non-triple negative cancer had a higher SUVmax compared with the non-recurrent group, though no significant difference in FDG uptake was noted between the recurrence and non-recurrent groups in subjects with triple-negative cancer. Lymph node involvement was the independent risk factor for cancer recurrence in the multivariate analysis. Conclusions In conclusion, high FDG uptake in primary breast tumors is significantly correlated with clinicopathological factors, such as tumor size, histologic grade, TNM stage, negativity of the hormonal receptor, HER2 overexpression and triple negativity. Therefore, FDG PET/CT is a helpful prognostic tool to direct the further management of patients with breast cancer.